Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

Hair loss treatments include medications and new methods like low-level light therapy, which may work by boosting cell activity and blood flow.

Dermatoscopy and videodermatoscopy are useful and reliable for tracking treatment progress in various skin conditions.

Psoriasis can cause temporary or permanent hair loss.

Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Hair microRNAs could be effective biomarkers for diagnosing scleroderma.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

More pediatric-specific research and guidelines are needed to improve hidradenitis suppurativa treatment in children and adolescents.

Autoimmune diseases can cause hair loss, and early treatment is important to prevent permanent damage.

Pregnancy can change skin disease severity, with some conditions improving and others worsening, and treatment should balance benefits and fetal safety.

Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.

Alopecia affects patients' quality of life, with younger patients and longer-lasting hair loss experiencing greater impact.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

The conclusion is that better understanding and more research are needed to effectively manage follicular and scarring disorders in skin of color, with an emphasis on patient education and cultural awareness.

The document concludes that treating tough skin disease in lupus involves sun protection, steroids, antimalarials, and various other therapies chosen based on individual risks and benefits.

People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.

The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.

Autoimmune liver diseases are likely linked to certain skin conditions like vitiligo and psoriasis.

Deoxycholic acid is effective for reducing chin fat but can cause side effects and serious complications, so careful patient evaluation is needed.

The document concludes that certain mutations may contribute to the inflammation in hidradenitis suppurativa and suggests that targeting TNFα could be a treatment strategy.

Dapsone improved pustular psoriasis in patients who didn't respond to other treatments and is considered a well-tolerated option.

Microneedle technology is beneficial for drug delivery and could make vaccinations cheaper and more accessible.

Some growth factors, while important for normal body functions, can cause diseases when not regulated properly.

The document concludes that eyelash trichomegaly, which is the abnormal growth of eyelashes, can be present from birth, caused by diseases, or result from certain medications.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.